nnoventric is dedicated to the development sophisticated transcatheter solutions for patients with severe heart diseases
Employees: 11-50
Total raised: $28.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.10.2024 | Series B | $28.5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 31.10.2024 | Innoventric's $28.5M Funding: A Leap Towards Revolutionizing Heart Care | In the world of medical innovation, few things are as crucial as effective treatments for heart conditions. Innoventric, a New York City-based company, is making waves with its recent $28.5 million Series B funding round. This investment is... |
| 30.10.2024 | Innoventric Secures $28.5M to Expand Transcatheter Tricuspid Valve Treatment | What You Should Know: – Innoventric, a leader in transcatheter tricuspid regurgitation (TR) treatment, today announced a $28.5 million Series B funding round to advance its revolutionary cross-caval technology, bringing the total funds rais... |
| 29.10.2024 | Innoventric Raises $28.5M in Series B Funding | Innoventric, a NYC-based company which specializes in transcatheter tricuspid regurgitation (TR) treatment, raised $28.5M in Series B funding. The round was led by RA Capital Management, with participation from the European Investment Commi... |
| - | INNOVENTRIC | “Innoventric introduces a novel transcatheter approach, simplifying the complex challenge of treating tricuspid regurgitation. Our solution is designed with both the physician and patient in mind, offering a safe and effective treatment, vi... |